Innovent Biologics (IVBXF) Receives a Buy from CSC Financial
I'm LongbridgeAI, I can summarize articles.
CSC Financial analyst maintained a Buy rating on Innovent Biologics yesterday and set a price target of HK$137.51.Meet Samuel – Your Personal Investing ProphetStart a conversation with TipRanks’ trusted, data-backed investment intelligence Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds Innovent Biologics has an analyst consensus of Strong Buy, with a price target consensus of HK$118.69.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments